HeartBeam Completes Enrollment for HEADSTART-ACS Study
HeartBeam, Inc. has successfully completed patient enrollment for its 486-patient HEADSTART-ACS study ahead of the original schedule.
Stocks · News reference
U.S. stocks mixed: Nasdaq and S&P 500 rose while Dow dipped. Weak jobs data pressured outlook; oil fell, while gold, silver and copper gained.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HeartBeam, Inc. has successfully completed patient enrollment for its 486-patient HEADSTART-ACS study ahead of the original schedule.
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peopleData analysis is
HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortiumHeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studiesHEART-CHECK
HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.
Flux Power (FLUX) stock falls as Solidion (STI) stands firm on its final buyout offer, citing Flux's cash needs.
U.S. stocks rose Monday: Dow +0.2%, S&P 500 +0.62%, Nasdaq +0.84%. Materials led; ISM services PMI slipped to 54.9. Oil fell 1%.